PMC3505846

Greater adherence to transdermal nicotine patch use was significantly associated with higher odds of achieving smoking abstinence at end of treatment.

Effect: improvement; OR 1.06 per patch used; CI: 95% CI: 1.03-1.08

Greater adherence to transdermal nicotine patch use was significantly associated with higher odds of achieving smoking abstinence at end of treatment.

Effect: improvement; OR 1.06 per patch used; CI: 95% CI: 1.03-1.08

Greater adherence to transdermal nicotine patch use was significantly associated with higher odds of achieving smoking abstinence at end of treatment.

Effect: improvement; OR 1.06 per patch used; CI: 95% CI: 1.03-1.08

Greater adherence to transdermal nicotine patch use was significantly associated with higher odds of achieving smoking abstinence at end of treatment.

Effect: improvement; OR 1.06 per patch used; CI: 95% CI: 1.03-1.08

Greater adherence to transdermal nicotine patch use was significantly associated with higher odds of achieving smoking abstinence at end of treatment.

Effect: improvement; OR 1.06 per patch used; CI: 95% CI: 1.03-1.08

Greater adherence to transdermal nicotine patch use was significantly associated with higher odds of achieving smoking abstinence at end of treatment.

Effect: improvement; OR 1.06 per patch used; CI: 95% CI: 1.03-1.08

Greater adherence to transdermal nicotine patch use was significantly associated with higher odds of achieving smoking abstinence at end of treatment.

Effect: improvement; OR 1.06 per patch used; CI: 95% CI: 1.03-1.08

Greater adherence to transdermal nicotine patch use was significantly associated with higher odds of achieving smoking abstinence at end of treatment.

Effect: improvement; OR 1.06 per patch used; CI: 95% CI: 1.03-1.08

Greater adherence to transdermal nicotine patch use was significantly associated with higher odds of achieving smoking abstinence at end of treatment.

Effect: improvement; OR 1.06 per patch used; CI: 95% CI: 1.03-1.08

Greater adherence to transdermal nicotine patch use was significantly associated with higher odds of achieving smoking abstinence at end of treatment.

Effect: improvement; OR 1.06 per patch used; CI: 95% CI: 1.03-1.08

Greater adherence to transdermal nicotine patch use was significantly associated with higher odds of achieving smoking abstinence at end of treatment.

Effect: improvement; OR 1.06 per patch used; CI: 95% CI: 1.03-1.08

Greater adherence to transdermal nicotine patch use was significantly associated with higher odds of achieving smoking abstinence at end of treatment.

Effect: improvement; OR 1.06 per patch used; CI: 95% CI: 1.03-1.08

Greater adherence to transdermal nicotine patch use was significantly associated with higher odds of achieving smoking abstinence at end of treatment.

Effect: improvement; OR 1.06 per patch used; CI: 95% CI: 1.03-1.08

Greater adherence to transdermal nicotine patch use was significantly associated with higher odds of achieving smoking abstinence at end of treatment.

Effect: improvement; OR 1.06 per patch used; CI: 95% CI: 1.03-1.08

Greater adherence to transdermal nicotine patch use was significantly associated with higher odds of achieving smoking abstinence at end of treatment.

Effect: improvement; OR 1.06 per patch used; CI: 95% CI: 1.03-1.08

Greater adherence to transdermal nicotine patch use was significantly associated with higher odds of achieving smoking abstinence at end of treatment.

Effect: improvement; OR 1.06 per patch used; CI: 95% CI: 1.03-1.08

Greater adherence to transdermal nicotine patch use was significantly associated with higher odds of achieving smoking abstinence at end of treatment.

Effect: improvement; OR 1.06 per patch used; CI: 95% CI: 1.03-1.08

Greater adherence to transdermal nicotine patch use was significantly associated with higher odds of achieving smoking abstinence at end of treatment.

Effect: improvement; OR 1.06 per patch used; CI: 95% CI: 1.03-1.08

Greater adherence to transdermal nicotine patch use was significantly associated with higher odds of achieving smoking abstinence at end of treatment.

Effect: improvement; OR 1.06 per patch used; CI: 95% CI: 1.03-1.08

Greater adherence to transdermal nicotine patch use was significantly associated with higher odds of achieving smoking abstinence at end of treatment.

Effect: improvement; OR 1.06 per patch used; CI: 95% CI: 1.03-1.08

Greater adherence to transdermal nicotine patch use was significantly associated with higher odds of achieving smoking abstinence at end of treatment.

Effect: improvement; OR 1.06 per patch used; CI: 95% CI: 1.03-1.08

Greater adherence to transdermal nicotine patch use was significantly associated with higher odds of achieving smoking abstinence at end of treatment.

Effect: improvement; OR 1.06 per patch used; CI: 95% CI: 1.03-1.08

Greater adherence to transdermal nicotine patch use was significantly associated with higher odds of achieving smoking abstinence at end of treatment.

Effect: improvement; OR 1.06 per patch used; CI: 95% CI: 1.03-1.08

Greater adherence to transdermal nicotine patch use was significantly associated with higher odds of achieving smoking abstinence at end of treatment.

Effect: improvement; OR 1.06 per patch used; CI: 95% CI: 1.03-1.08

Greater adherence to transdermal nicotine patch use was significantly associated with higher odds of achieving smoking abstinence at end of treatment.

Effect: improvement; OR 1.06 per patch used; CI: 95% CI: 1.03-1.08

Greater adherence to transdermal nicotine patch use was significantly associated with higher odds of achieving smoking abstinence at end of treatment.

Effect: improvement; OR 1.06 per patch used; CI: 95% CI: 1.03-1.08

Greater adherence to transdermal nicotine patch use was significantly associated with higher odds of achieving smoking abstinence at end of treatment.

Effect: improvement; OR 1.06 per patch used; CI: 95% CI: 1.03-1.08

Among smokers with unipolar depressive disorders who entered the trial with low depressive symptoms, achieving smoking abstinence was associated with a significantly higher rate of worsening depressiv

Effect: decline; 56% (35/63) vs 27% (6/22), Chi2=4.60, p=0.032

Among smokers with unipolar depressive disorders who entered the trial with low depressive symptoms, achieving smoking abstinence was associated with a significantly higher rate of worsening depressiv

Effect: decline; 56% (35/63) vs 27% (6/22), Chi2=4.60, p=0.032

Among smokers with unipolar depressive disorders who entered the trial with low depressive symptoms, achieving smoking abstinence was associated with a significantly higher rate of worsening depressiv

Effect: decline; 56% (35/63) vs 27% (6/22), Chi2=4.60, p=0.032

Among smokers with unipolar depressive disorders who entered the trial with low depressive symptoms, achieving smoking abstinence was associated with a significantly higher rate of worsening depressiv

Effect: decline; 56% (35/63) vs 27% (6/22), Chi2=4.60, p=0.032

Among smokers with unipolar depressive disorders who entered the trial with low depressive symptoms, achieving smoking abstinence was associated with a significantly higher rate of worsening depressiv

Effect: decline; 56% (35/63) vs 27% (6/22), Chi2=4.60, p=0.032

Among smokers with unipolar depressive disorders who entered the trial with low depressive symptoms, achieving smoking abstinence was associated with a significantly higher rate of worsening depressiv

Effect: decline; 56% (35/63) vs 27% (6/22), Chi2=4.60, p=0.032

Among smokers with unipolar depressive disorders who entered the trial with low depressive symptoms, achieving smoking abstinence was associated with a significantly higher rate of worsening depressiv

Effect: decline; 56% (35/63) vs 27% (6/22), Chi2=4.60, p=0.032

Among smokers with unipolar depressive disorders who entered the trial with low depressive symptoms, achieving smoking abstinence was associated with a significantly higher rate of worsening depressiv

Effect: decline; 56% (35/63) vs 27% (6/22), Chi2=4.60, p=0.032

Among smokers with unipolar depressive disorders who entered the trial with low depressive symptoms, achieving smoking abstinence was associated with a significantly higher rate of worsening depressiv

Effect: decline; 56% (35/63) vs 27% (6/22), Chi2=4.60, p=0.032

Among smokers with unipolar depressive disorders who entered the trial with low depressive symptoms, achieving smoking abstinence was associated with a significantly higher rate of worsening depressiv

Effect: decline; 56% (35/63) vs 27% (6/22), Chi2=4.60, p=0.032

Among smokers with unipolar depressive disorders who entered the trial with low depressive symptoms, achieving smoking abstinence was associated with a significantly higher rate of worsening depressiv

Effect: decline; 56% (35/63) vs 27% (6/22), Chi2=4.60, p=0.032

Among smokers with unipolar depressive disorders who entered the trial with low depressive symptoms, achieving smoking abstinence was associated with a significantly higher rate of worsening depressiv

Effect: decline; 56% (35/63) vs 27% (6/22), Chi2=4.60, p=0.032

Among smokers with unipolar depressive disorders who entered the trial with low depressive symptoms, achieving smoking abstinence was associated with a significantly higher rate of worsening depressiv

Effect: decline; 56% (35/63) vs 27% (6/22), Chi2=4.60, p=0.032

Among smokers with unipolar depressive disorders who entered the trial with low depressive symptoms, achieving smoking abstinence was associated with a significantly higher rate of worsening depressiv

Effect: decline; 56% (35/63) vs 27% (6/22), Chi2=4.60, p=0.032

Among smokers with unipolar depressive disorders who entered the trial with low depressive symptoms, achieving smoking abstinence was associated with a significantly higher rate of worsening depressiv

Effect: decline; 56% (35/63) vs 27% (6/22), Chi2=4.60, p=0.032

Among smokers with unipolar depressive disorders who entered the trial with low depressive symptoms, achieving smoking abstinence was associated with a significantly higher rate of worsening depressiv

Effect: decline; 56% (35/63) vs 27% (6/22), Chi2=4.60, p=0.032

Among smokers with unipolar depressive disorders who entered the trial with low depressive symptoms, achieving smoking abstinence was associated with a significantly higher rate of worsening depressiv

Effect: decline; 56% (35/63) vs 27% (6/22), Chi2=4.60, p=0.032

Among smokers with unipolar depressive disorders who entered the trial with low depressive symptoms, achieving smoking abstinence was associated with a significantly higher rate of worsening depressiv

Effect: decline; 56% (35/63) vs 27% (6/22), Chi2=4.60, p=0.032

Among smokers with unipolar depressive disorders who entered the trial with low depressive symptoms, achieving smoking abstinence was associated with a significantly higher rate of worsening depressiv

Effect: decline; 56% (35/63) vs 27% (6/22), Chi2=4.60, p=0.032

Among smokers with unipolar depressive disorders who entered the trial with low depressive symptoms, achieving smoking abstinence was associated with a significantly higher rate of worsening depressiv

Effect: decline; 56% (35/63) vs 27% (6/22), Chi2=4.60, p=0.032

Among smokers with unipolar depressive disorders who entered the trial with low depressive symptoms, achieving smoking abstinence was associated with a significantly higher rate of worsening depressiv

Effect: decline; 56% (35/63) vs 27% (6/22), Chi2=4.60, p=0.032

Among smokers with unipolar depressive disorders who entered the trial with low depressive symptoms, achieving smoking abstinence was associated with a significantly higher rate of worsening depressiv

Effect: decline; 56% (35/63) vs 27% (6/22), Chi2=4.60, p=0.032

Among smokers with unipolar depressive disorders who entered the trial with low depressive symptoms, achieving smoking abstinence was associated with a significantly higher rate of worsening depressiv

Effect: decline; 56% (35/63) vs 27% (6/22), Chi2=4.60, p=0.032